We compared the CCNE1 amplification rate in untreated tumors versus tumors exposed to prior therapy and observed a higher frequency of CCNE1 amplification in untreated EA but no difference in the other EGC subtypes (Supplementary Fig. S1), suggesting that CCNE1 amplification is likely present at diagnosis prior to therapy. This evidence concerns the gene CCNE1 and Esophageal atresia.